Rock Creek Group’s MaxCyte MXCT Stock Holding History

Rock Creek Group’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-52,684	Closed	-$340K	–	204
2021 Q4	$340K	Buy	+52,684	New	+$566K	0.05%	111

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Rock Creek Group's MXCT Position: Q1 2022 in Review

Rock Creek Group sold out of MaxCyte (MXCT) in Q1 2022, closing a stake of 52,684 shares — an estimated $340K sold.

Rock Creek Group first reported a position in MXCT in Q4 2021 and held it in 1 quarter. The position peaked at $340K in Q4 2021. 98 funds tracked by Wall St. Rank hold MXCT as of Q1 2022.

Rock Creek Group reported no remaining MaxCyte position as of Q1 2022 after selling out during the quarter.
Rock Creek Group sold 52,684 MaxCyte shares in Q1 2022, an estimated $340K.
Rock Creek Group first reported a position in MaxCyte in Q4 2021 and held it in 1 quarter.
Rock Creek Group's MaxCyte position peaked at $340K in Q4 2021.
98 funds tracked by Wall St. Rank held MaxCyte as of Q1 2022.

Based on Rock Creek Group's 13F filing for Q1 2022, filed 11 May 2022.